Trial Profile
Plasma Amyloid Beta Species After a Single Solanezumab Infusion in Nondemented Individuals and Those With Mild Dementia of the Alzheimer's Type.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Solanezumab (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacodynamics
- Sponsors Eli Lilly and Company
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2012 Planned end date changed from 1 Jun 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.